Media & Press Updates
What Happened in 2015
Richter and Evestra enter into collaboration agreement
February 9, 2015
BUDAPEST, Hungary and SAN ANTONIO, Texas – Gedeon Richter Plc. and Evestra Inc. today announced that they have signed a collaboration agreement in which Richter is providing a USD $5-million convertible loan to Evestra. The funds will empower Evestra to accelerate the development of its innovative women’s health product pipeline into clinical stages. Under the terms of the agreement, after three years Richter has an option to decide whether the loan is to be reimbursed, including earned interest, or converted into an equity stake in Evestra.
About Gedeon Richter
Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.1 billion (USD$ 1.5 billion), while its market capitalization amounted to EUR 2.1 billion (USD$ 2.5 billion) in 2014. The product portfolio of Richter covers almost all important therapeutic areas, including gynecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.
Evestra Inc. (), is a San Antonio, Texas-based biopharmaceutical company engaged in the development of innovative women’s healthcare products. Evestra’s products are based on two platform technologies, medicinal chemistry and vaginal drug delivery technology, and address unmet medical needs in women's health
Evestra announced today that the US Patent Office has allowed the second patent in the antiprogestin area
April 23, 2015
Evestra announced today that the US Patent Office has allowed the second patent in the antiprogestin area which describes imidazolyl-based steroidal new chemical entities. These compounds have potentially a broad range of applications in oncology and gynecological indications. The description of these compounds and their antagonistic/agonistic biological properties was published in 2014 in the journal Steroids in a paper entitled “Synthesis and biological evaluation of 11’ imidazolyl antiprogestins and mesoprogestins”, Vol. 92, pages 45-55.
Evestra has announced today the launch of Evestra Onkologia Sp. Z o.o.
April 24, 2015
Evestra has announced today the launch of Evestra Onkologia Sp. Z o.o, as its wholly-owned subsidiary in Poland. The newly established company will be fully dedicated to research and development activities as they pertain to oncology therapeutics, as well as a product portfolio initially based on product concepts developed by Evestra Inc.
Evestra Onkologia will collaborate with Polish academic institutions and companies involved in oncology basic research, preclinical, and clinical development. Evestra Onkologia is located in the city Nowy Dwor Mazowiecki, about 18 miles northwest of Warsaw, with easy access to other Polish and European cities via Modlin airport located in Nowy Dwor Mazowiecki.